Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Roche Holding AG Basel American Depositary Shares (OP: RHHBY )

46.76 USD -0.27 (-0.57%)
Official Closing Price Updated: 4:00 PM EDT, Jul 26, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,725,426
Open 46.78
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 47.03
Today's Range 46.64 - 47.03
52wk Range 39.72 - 48.78
Shares Outstanding N/A
Dividend Yield 1.96%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Spark Therapeutics’ SPK-8011 Suggests Stable and Durable Factor VIII Expression in Largest Phase 1/2 Gene Therapy Study in Hemophilia A to Date
From GlobeNewswire News Releases
FDA Grants Breakthrough Therapy Designation for Venclexta in Combination With Azacitidine for the Treatment of Patients With Myelodysplastic Syndromes
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that Venclexta® (venetoclax) in combination with azacitidine has been granted Breakthrough Therapy Designation (BTD)... 
From Business Wire News Releases

Performance

YTD
+6.56%
+6.56%
1 Month
-1.50%
-1.50%
3 Month
+11.92%
+11.92%
6 Month
+2.32%
+2.32%
1 Year
+6.81%
+6.81%

More News

Read More
Roche Puts Alzheimer's Candidate, Gantenerumab In Spotlight; In Dialogue with FDA: Reuters
Tags Health Care RHHBY FDA
From Benzinga
New Data for Genentech’s Hemlibra (emicizumab-kxwh) Reinforce Safety Profile in People With Hemophilia A
From Business Wire News Releases
Rebound In COVID-19 Tests Lift Roche's Half-Year Sales, Oncology Still Hit By Biosimilars, Pandemic
Tags Biotech Guidance Earnings
From Benzinga
Spark Therapeutics' Hemophilia Gene Therapy Achieve Stable, Durable FVIII Expression
Tags News Hemophilia A RHHBY
From Benzinga
AbbVie - Roche's Venclexta Receives Breakthrough Therapy Tag In High-Risk Myelodysplastic Syndromes
Tags News RHHBF FDA
From Benzinga
Roche Unveils New Hemlibra Data Reinforcing Safety Profile In Hemophilia A
Tags RHHBY General Benzinga
From Benzinga
Celldex Stock Surges As It Touts Early-Stage Skin Disease Study Win For CDX-0159
Tags News Health Care RHHBY
From Benzinga
5 Stocks to Own for the Surge in Coronavirus Variants
Tags GILD MRNA Market News
From Motley Fool
3 Cathie Wood Stocks You Can Buy for Less Than $50
Tags ARKK RHHBY Market News
From Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.